News of Note—GlaxoSmithKline's Fluarix, CureVac and more

In this week's news of note, GlaxoSmithKline won a label expansion for Fluarix Quadrivalent. (Pixabay)

Here is some other vaccine news of note for the week:

> GlaxoSmithKline won an FDA label expansion for its Fluarix Quadrivalent. Children 6 months and older are now eligible for the flu vaccine. Release

> In its year-ahead preview at the J.P. Morgan Healthcare Conference, CureVac said it's planning phase 1 vaccine trials in rabies and seasonal flu, among its other programs. Release

> GeoVax's Ebola vaccine candidate protected 100% of macaques in a lethal challenge study. Release

> VBI Vaccines' phase 1/2a study of VBI-1901 in glioblastoma multiforme is underway as the first patient has been dosed. Release

> Novavax is planning to move from its current site in Gaithersburg, Maryland. Washington Business Journal article